Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations.
Sign Up to like & getrecommendations! Published in 2021 at "Current drug delivery"
DOI: 10.2174/1567201818666210910162750
Abstract: Alzheimer's disease (AD), a progressive and irreversible neurodegenerative disorder, is the most common form of dementia worldwide. Currently, there is no disease-modifying AD drug, and the development of effective treatments is made even harder by… read more here.
Keywords: preclinical evaluation; disease preclinical; nanotherapeutics alzheimer; evaluation clinical ... See more keywords
Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041054
Abstract: Alzheimer’s disease (AD) is the most prevalent form of dementia. It affects more than 30 million people worldwide and costs over US$ 1.3 trillion annually. AD is characterized by the brain accumulation of amyloid β… read more here.
Keywords: alzheimer disease; nanotherapeutics alzheimer; multifunctional nanotherapeutics; derivatives multifunctional ... See more keywords